These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31900680)

  • 1. In Vivo Stability of Therapeutic Proteins.
    Schuster J; Koulov A; Mahler HC; Detampel P; Huwyler J; Singh S; Mathaes R
    Pharm Res; 2020 Jan; 37(2):23. PubMed ID: 31900680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein drug delivery: current dosage form profile and formulation strategies.
    Geraldes DC; Beraldo-de-Araújo VL; Pardo BOP; Pessoa Junior A; Stephano MA; de Oliveira-Nascimento L
    J Drug Target; 2020 Apr; 28(4):339-355. PubMed ID: 31575296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of monoclonal antibodies after simulated subcutaneous administration.
    Schuster J; Mahler HC; Joerg S; Kamuju V; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Jun; 110(6):2386-2394. PubMed ID: 33722546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein formulation and fill-finish operations.
    Patro SY; Freund E; Chang BS
    Biotechnol Annu Rev; 2002; 8():55-84. PubMed ID: 12436915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment.
    Jogdeo CM; Bhattacharya DS; Lin V; Kolhe P; Badkar A
    J Pharm Sci; 2024 Jul; 113(7):1854-1864. PubMed ID: 38341129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Challenges Assessing Protein Aggregation and Fragmentation Under Physiologic Conditions.
    Schuster J; Mahler HC; Joerg S; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Sep; 110(9):3103-3110. PubMed ID: 33933436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of various analytical techniques in quality control of pharmaceutical excipients.
    Kumar M; Bhatia R; Rawal RK
    J Pharm Biomed Anal; 2018 Aug; 157():122-136. PubMed ID: 29787965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of stable lyophilized protein drug products.
    Remmele RL; Krishnan S; Callahan WJ
    Curr Pharm Biotechnol; 2012 Mar; 13(3):471-96. PubMed ID: 22283723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of water in the physical stability of solid dosage formulations.
    Airaksinen S; Karjalainen M; Shevchenko A; Westermarck S; Leppänen E; Rantanen J; Yliruusi J
    J Pharm Sci; 2005 Oct; 94(10):2147-65. PubMed ID: 16136577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric drug development: formulation considerations.
    Ali AA; Charoo NA; Abdallah DB
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine as an Excipient for Protein Freeze-Drying: A Mini Review.
    Stärtzel P
    J Pharm Sci; 2018 Apr; 107(4):960-967. PubMed ID: 29183741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.
    Kinnunen HM; Mrsny RJ
    J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Buffers in Protein Formulations.
    Zbacnik TJ; Holcomb RE; Katayama DS; Murphy BM; Payne RW; Coccaro RC; Evans GJ; Matsuura JE; Henry CS; Manning MC
    J Pharm Sci; 2017 Mar; 106(3):713-733. PubMed ID: 27894967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigating Cocrystal Physical Stability Liabilities in Preclinical Formulations.
    Bhardwaj S; Lipert M; Bak A
    J Pharm Sci; 2017 Jan; 106(1):31-38. PubMed ID: 27665129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid lipid excipients - matrix agents for sustained drug delivery.
    Rosiaux Y; Jannin V; Hughes S; Marchaud D
    J Control Release; 2014 Aug; 188():18-30. PubMed ID: 24929038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salt disproportionation: A material science perspective.
    Thakral NK; Kelly RC
    Int J Pharm; 2017 Mar; 520(1-2):228-240. PubMed ID: 28163222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.